§ Claim under review · Health
For years, creatine has been known primarily as a supplement for increasing strength and muscle mass. But new research is drawing attention to its potential effects on the brain. In several clinical studies involving women with major depressive disorder who also experienced anxiety symptoms, taking creatine daily alongside standard treatment led to improvements beginning as early as the first week. After just two weeks, anxiety symptoms had decreased by more than 50% in some participants... Reference: Dechent et al. – Translational Psychiatry: Review of the evidence on creatine and mental health (link to psychiatryonline.org 10.1176/appi.ajp.2012.12010009).
Verdict
Partially accurate but misleading
Confidence
HighSummary
The post links to a real 2012 randomized trial by Lyoo and colleagues in the American Journal of Psychiatry. That trial tested creatine added to the antidepressant escitalopram in 52 women with major depressive disorder, and it found faster and greater improvement in depression scores in the creatine group, with a difference from placebo emerging around week 2 and continuing through week 8. However, the trial measured depression, not anxiety, and its headline number was a roughly 52 percent remission rate at week 8, not a "more than 50 percent reduction in anxiety after two weeks." The post also cites "Dechent et al., Translational Psychiatry" as its source, but that reference does not match the linked paper and no such review could be located. Independent reviewers of the creatine mental health literature note that anxiety benefit has not been established in dedicated trials. So the science on creatine and depression augmentation in women is genuine, but the specific anxiety claim in this post is not supported by the cited study.
The readings
key figures from the evidenceCreatine group depression remission rate at week 8
Placebo group depression remission rate at week 8
Why this verdict
Evidence
The linked study (Lyoo et al. 2012) is a real, peer-reviewed RCT of 52 women with major depressive disorder taking escitalopram, randomized to add-on creatine (3 g/day for week 1, then 5 g/day) or placebo for 8 weeks. By week 8, mean HAM-D scores had decreased from 26.9 to 5.4 in the creatine group, versus 26.7 to 9.8 in the placebo group (p < 0.001) . By week 8, significantly more participants in the creatine group achieved remission compared to placebo (52.0% vs. 25.9%; p = 0.008). The trial reported improved response in the creatine group as early as week 2 according to the scores on HAMD, MADRS and CGI , not week 1. The primary outcomes were depression scales, not anxiety scales.
Independent summaries of the creatine mental-health literature note that anxiety improvement has not been conclusively demonstrated in large, stand-alone trials. More targeted studies are needed to determine whether creatine directly reduces anxiety symptoms.
Findings
✓ What's accurate 4
- A real RCT (Lyoo 2012) exists showing creatine augmentation of an SSRI accelerated and enhanced improvement in women with major depressive disorder.
- Improvements did emerge relatively early in the trial (by week 2) and continued through week 8.
- Proposed mechanisms in the literature do include brain energy metabolism, mitochondrial function, and neurotransmitter modulation.
- Interest in creatine for psychiatric/brain applications has genuinely grown.
≈ What's misleading 5
- **Depression relabeled as anxiety.** The linked Lyoo 2012 study measured depression (HAM-D, MADRS, CGI). The post repeatedly frames the outcome as "anxiety symptoms." This is a category swap, not a summary.
- **"More than 50% reduction in anxiety after two weeks."** No such anxiety result is reported in Lyoo 2012. The 50%-ish figures in the actual study relate to *depression remission at week 8* (52% vs 25.9%), not two-week anxiety reduction.
- **Timing exaggeration.** The claim says improvements began "as early as the first week." The published trial reports the separation from placebo starting at week 2.
- **"Several clinical studies."** The specific women-with-MDD finding rests largely on a single small RCT (n=52), plus a related imaging follow-up in the same cohort. Bipolar and CBT-augmentation trials exist but do not replicate the specific anxiety framing.
- **Citation mismatch / likely fabricated reference.** The post cites "Dechent et al. – Translational Psychiatry: Review of the evidence on creatine and mental health," but the URL points to Lyoo et al. 2012 in the American Journal of Psychiatry. No Dechent review in Translational Psychiatry on this topic could be located.
? What's uncertain 2
- Whether the post's author intended to refer to a specific anxiety subscale within HAM-D (which contains anxiety/somatic items). Even if so, "anxiety symptoms decreased more than 50% in two weeks" is not a headline finding of the paper.
- Whether "Dechent et al." is a genuine but mis-cited paper or an invented reference.
Sources
1 of 5 linked to recordsLyoo IK, Yoon S, Kim TS, et al. (2012), *American Journal of Psychiatry* 169(9): 937–945, "A Randomized, Double-Blind Placebo-Controlled Trial of Oral Creatine Monohydrate Augmentation for Enhanced Response to a Selective Serotonin Reuptake Inhibitor in Women With Major Depressive Disorder." Primary source. Peer-reviewed RCT. (This is the article the post's URL actually points to.)
Yoon S, Kim JE, Hwang J, ... Lyoo IK (2016), *Biological Psychiatry* 80(6): 439–447, follow-on imaging analysis of the Lyoo 2012 cohort. Primary.
Toniolo RA et al. (2018), PMC5775367, RCT of creatine in bipolar depression. Primary.
Secondary explainers (Psychiatry & Psychotherapy Podcast Ep. 238; Principia Scientific summary). Secondary.
"Dechent et al. – Translational Psychiatry: Review of the evidence on creatine and mental health"